These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

497 related articles for article (PubMed ID: 20453058)

  • 21. Preclinical assessment of the absorption and disposition of the phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor GDC-0980 and prediction of its pharmacokinetics and efficacy in human.
    Salphati L; Pang J; Plise EG; Lee LB; Olivero AG; Prior WW; Sampath D; Wong S; Zhang X
    Drug Metab Dispos; 2012 Sep; 40(9):1785-96. PubMed ID: 22696419
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer .
    Folkes AJ; Ahmadi K; Alderton WK; Alix S; Baker SJ; Box G; Chuckowree IS; Clarke PA; Depledge P; Eccles SA; Friedman LS; Hayes A; Hancox TC; Kugendradas A; Lensun L; Moore P; Olivero AG; Pang J; Patel S; Pergl-Wilson GH; Raynaud FI; Robson A; Saghir N; Salphati L; Sohal S; Ultsch MH; Valenti M; Wallweber HJ; Wan NC; Wiesmann C; Workman P; Zhyvoloup A; Zvelebil MJ; Shuttleworth SJ
    J Med Chem; 2008 Sep; 51(18):5522-32. PubMed ID: 18754654
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Correlation of PIK3Ca mutations with gene expression and drug sensitivity in NCI-60 cell lines.
    Whyte DB; Holbeck SL
    Biochem Biophys Res Commun; 2006 Feb; 340(2):469-75. PubMed ID: 16376301
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Modulators of sensitivity and resistance to inhibition of PI3K identified in a pharmacogenomic screen of the NCI-60 human tumor cell line collection.
    Kwei KA; Baker JB; Pelham RJ
    PLoS One; 2012; 7(9):e46518. PubMed ID: 23029544
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Identification of subtypes in human epidermal growth factor receptor 2--positive breast cancer reveals a gene signature prognostic of outcome.
    Staaf J; Ringnér M; Vallon-Christersson J; Jönsson G; Bendahl PO; Holm K; Arason A; Gunnarsson H; Hegardt C; Agnarsson BA; Luts L; Grabau D; Fernö M; Malmström PO; Johannsson OT; Loman N; Barkardottir RB; Borg A
    J Clin Oncol; 2010 Apr; 28(11):1813-20. PubMed ID: 20231686
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Anticancer activity of litchi fruit pericarp extract against human breast cancer in vitro and in vivo.
    Wang X; Yuan S; Wang J; Lin P; Liu G; Lu Y; Zhang J; Wang W; Wei Y
    Toxicol Appl Pharmacol; 2006 Sep; 215(2):168-78. PubMed ID: 16563451
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Using a xenograft model of human breast cancer metastasis to find genes associated with clinically aggressive disease.
    Kluger HM; Chelouche Lev D; Kluger Y; McCarthy MM; Kiriakova G; Camp RL; Rimm DL; Price JE
    Cancer Res; 2005 Jul; 65(13):5578-87. PubMed ID: 15994930
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Preclinical in vitro models from genetically engineered mice for breast and colon cancer (Review).
    Telang N; Katdare M
    Oncol Rep; 2011 May; 25(5):1195-201. PubMed ID: 21399881
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ellagic Acid Enhances the Efficacy of PI3K Inhibitor GDC-0941 in Breast Cancer Cells.
    Shi L; Gao X; Li X; Jiang N; Luo F; Gu C; Chen M; Cheng H; Liu P
    Curr Mol Med; 2015; 15(5):478-86. PubMed ID: 25941816
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Molecular changes associated with the agonist activity of hydroxy-tamoxifen and the hyper-response to estradiol in hydroxy-tamoxifen-resistant breast cancer cell lines.
    Vendrell JA; Bieche I; Desmetz C; Badia E; Tozlu S; Nguyen C; Nicolas JC; Lidereau R; Cohen PA
    Endocr Relat Cancer; 2005 Mar; 12(1):75-92. PubMed ID: 15788640
    [TBL] [Abstract][Full Text] [Related]  

  • 31. De novo discovery of a gamma-secretase inhibitor response signature using a novel in vivo breast tumor model.
    Watters JW; Cheng C; Majumder PK; Wang R; Yalavarthi S; Meeske C; Kong L; Sun W; Lin J; Heyer J; Ware C; Winter C; Reilly JF; Demuth T; Clark S; Chiu MI; Robinson MO; Kohl N; Kannan K
    Cancer Res; 2009 Dec; 69(23):8949-57. PubMed ID: 19903844
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antitumor activity of HKI-272, an orally active, irreversible inhibitor of the HER-2 tyrosine kinase.
    Rabindran SK; Discafani CM; Rosfjord EC; Baxter M; Floyd MB; Golas J; Hallett WA; Johnson BD; Nilakantan R; Overbeek E; Reich MF; Shen R; Shi X; Tsou HR; Wang YF; Wissner A
    Cancer Res; 2004 Jun; 64(11):3958-65. PubMed ID: 15173008
    [TBL] [Abstract][Full Text] [Related]  

  • 33. PIK3CA mutation sensitizes breast cancer cells to synergistic therapy of PI3K inhibition and AMPK activation.
    Liu S; Tang Y; Yan M; Jiang W
    Invest New Drugs; 2018 Oct; 36(5):763-772. PubMed ID: 29504069
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The selective class I PI3K inhibitor CH5132799 targets human cancers harboring oncogenic PIK3CA mutations.
    Tanaka H; Yoshida M; Tanimura H; Fujii T; Sakata K; Tachibana Y; Ohwada J; Ebiike H; Kuramoto S; Morita K; Yoshimura Y; Yamazaki T; Ishii N; Kondoh O; Aoki Y
    Clin Cancer Res; 2011 May; 17(10):3272-81. PubMed ID: 21558396
    [TBL] [Abstract][Full Text] [Related]  

  • 35. KDM6B Counteracts EZH2-Mediated Suppression of
    Wang W; Lim KG; Feng M; Bao Y; Lee PL; Cai Y; Chen Y; Zhang H; Marzese D; Hoon DSB; Yu Q
    Mol Cancer Ther; 2018 Sep; 17(9):1973-1983. PubMed ID: 29925528
    [TBL] [Abstract][Full Text] [Related]  

  • 36. PK-PD modeling of combination efficacy effect from administration of the MEK inhibitor GDC-0973 and PI3K inhibitor GDC-0941 in A2058 xenografts.
    Choo EF; Ng CM; Berry L; Belvin M; Lewin-Koh N; Merchant M; Salphati L
    Cancer Chemother Pharmacol; 2013 Jan; 71(1):133-43. PubMed ID: 23053270
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The PI3K inhibitor GDC-0941 displays promising in vitro and in vivo efficacy for targeted medulloblastoma therapy.
    Ehrhardt M; Craveiro RB; Holst MI; Pietsch T; Dilloo D
    Oncotarget; 2015 Jan; 6(2):802-13. PubMed ID: 25596739
    [TBL] [Abstract][Full Text] [Related]  

  • 38. GDC-0941 and CXCL8 (3-72) K11R/G31P combination therapy confers enhanced efficacy against breast cancer.
    Li X; Zhang Y; Walana W; Zhao F; Li F; Luo F
    Future Oncol; 2020 May; 16(14):911-921. PubMed ID: 32285685
    [No Abstract]   [Full Text] [Related]  

  • 39. [18F]-FLT positron emission tomography can be used to image the response of sensitive tumors to PI3-kinase inhibition with the novel agent GDC-0941.
    Cawthorne C; Burrows N; Gieling RG; Morrow CJ; Forster D; Gregory J; Radigois M; Smigova A; Babur M; Simpson K; Hodgkinson C; Brown G; McMahon A; Dive C; Hiscock D; Wilson I; Williams KJ
    Mol Cancer Ther; 2013 May; 12(5):819-28. PubMed ID: 23427298
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Identification of candidate molecular markers predicting sensitivity in solid tumors to dasatinib: rationale for patient selection.
    Huang F; Reeves K; Han X; Fairchild C; Platero S; Wong TW; Lee F; Shaw P; Clark E
    Cancer Res; 2007 Mar; 67(5):2226-38. PubMed ID: 17332353
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.